Innovator’s Pitch Challenge
The mission of the Gateway Biotechnology Corporation (GBC) is to develop new therapies for hearing disorders such as hearing loss and tinnitus, for which no medications are currently available. As its first line of product development, GBC has established technology platforms to identify drug candidates for treating hearing loss or tinnitus. Four drug developing programs have been established. Among them, GW-HP1, a drug candidate funded by the U.S. army, is currently at a Phase II clinical trial to prevent noise-induced hearing loss; GW-TT2, a drug candidate for tinnitus, has been received a favorable FDA response for its pre-IND application. Recently, our new gene therapy application for tinnitus received a strong positive response from an expert review panel at National Institute for Health.